Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US75886F1075
Ticker REGN
Company REGENERON PHARMACEUTICALS
Currency $
Price
Aware Investor Index (AII) 0.0223
Recommendation SELL
P/E 55.59
ROE 7.17 %
Capitalization 34,927,900,000 $
Dividend Yield 0.00 %
P/S 5.20
AII Position 574
P/E Position 602
ROE Position 525
Capitalization Position 261
Dividend Yield Position 594
Sales 6,710,800,000 $
10-Year Average Earnings 628,256,400 $
Shares Outstanding 114,800,000
Equity 8,757,300,000 $
Dividend per Share 0 $
Industry Pharmaceutical
Country United States
REGENERON PHARMACEUTICALS Investor Relations Web Site http://investor.regeneron.com/







Sales:

YEAR MONTH AMOUNT
2018 12 6,710,800,000.00 $
2017 12 5,872,227,000.00 $
2016 12 4,860,427,000.00 $
2015 12 4,103,728,000.00 $
2014 12 2,819,557,000.00 $
2013 12 2,104,745,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 12 2,444,400,000.00 $
2017 12 1,198,511,000.00 $
2016 12 895,522,000.00 $
2015 12 636,056,000.00 $
2014 12 338,126,000.00 $
2013 12 413,738,000.00 $
2012 12 750,269,000.00 $
2011 12 -221,760,000.00 $
2010 12 -104,468,000.00 $
2009 12 -67,830,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 12 8,757,300,000.00 $
2017 12 6,144,078,000.00 $
2016 12 4,449,245,000.00 $
2015 12 3,654,837,000.00 $
2014 12 2,542,325,000.00 $
2013 12 1,952,076,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 114,800,000
2017 12 115,954,000
2016 12 116,367,000
2015 12 115,230,000
2014 12 113,413,000
2013 12 111,290,000

 












Bloomberg News for REGENERON PHARMACEUTICALS:



Google News for REGENERON PHARMACEUTICALS:

Find News - 35 minutes ago
Regeneron Pharmaceuticals, Inc. (REGN) Stock Down -2.49 ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the top losers of the stock market today, sinking -2.49% or (-7.8 points) to $305.1 ...
Garland Gazette
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insiders Have ...
So we'll take a look at whether insiders have been buying or selling shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Stocks Beat
Bbva Compass Bancshares Upped Regeneron Pharmaceuticals ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 1.19% ... 03/04/2018 – REGENERON PHARMACEUTICALS INC REGN.
Rockland Register
Contrasting of BioPharmX Corporation (BPMX) and Regeneron ...
BioPharmX Corporation (NYSEAMERICAN:BPMX) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) compete with each other in the ...
Yahoo Finance - 12 Jun 2019
FDA OKs new use for Regeneron and Sanofi's Dupixent
Regeneron Pharmaceuticals (REGN -2.3%) and commercialization partner Sanofi (SNY -0.6%) announce the FDA nod for Dupixent ...
Stocks Beat
Here's What Hedge Funds Think About Regeneron Pharmaceuticals ...
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has experienced a decrease in support from the world's most elite money managers lately.
Rockland Register
Regeneron loses a bull as threats to Eylea rise
Argus Research analysts Jasper Hellweg and Kelly Hannigan see threats to Regeneron Pharmaceuticals' (REGN +1.2%) main revenue driver, ...
Mayfield Recorder
The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi ...
The FDA will announce its decision on Sanofi SA (NASDAQ: SNY) & Regeneron Pharmaceuticals Inc (NASDAQ: REGN)'s sNDA for Dupixent ...
Stocks Beat - 1 day ago
Here's Why Regeneron Pharmaceuticals Tumbled 12% in May
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) fell 12.1% in May, according to data provided by S&P Global Market Intelligence, ...
Stocks Beat - 2 days ago
Implied Volatility Surging for Regeneron (REGN) Stock Options
Investors in Regeneron Pharmaceuticals, Inc. REGN need to pay close attention to the stock based on moves in the options market lately.


Back